A detailed history of Bank Of America Corp transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 531,557 shares of VYGR stock, worth $3.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
531,557
Previous 648,760 18.07%
Holding current value
$3.14 Million
Previous $5.13 Million 39.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.77 - $9.27 $676,261 - $1.09 Million
-117,203 Reduced 18.07%
531,557 $3.11 Million
Q2 2024

Aug 14, 2024

BUY
$7.42 - $10.54 $2.18 Million - $3.1 Million
294,317 Added 83.04%
648,760 $5.13 Million
Q1 2024

May 15, 2024

BUY
$7.15 - $10.84 $2.48 Million - $3.76 Million
346,741 Added 4501.96%
354,443 $3.3 Million
Q4 2023

Feb 14, 2024

SELL
$6.28 - $8.81 $124,344 - $174,438
-19,800 Reduced 71.99%
7,702 $65,000
Q2 2023

Aug 14, 2023

SELL
$6.94 - $13.99 $139,681 - $281,576
-20,127 Reduced 42.26%
27,502 $314,000
Q1 2023

May 12, 2023

BUY
$6.0 - $10.78 $188,280 - $338,276
31,380 Added 193.12%
47,629 $367,000
Q4 2022

Feb 10, 2023

BUY
$4.94 - $6.61 $14,987 - $20,054
3,034 Added 22.96%
16,249 $99,000
Q3 2022

Nov 14, 2022

SELL
$5.57 - $7.47 $145,794 - $195,527
-26,175 Reduced 66.45%
13,215 $78,000
Q2 2022

Aug 12, 2022

SELL
$4.82 - $10.09 $233,659 - $489,132
-48,477 Reduced 55.17%
39,390 $232,000
Q1 2022

May 16, 2022

BUY
$2.75 - $9.44 $208,081 - $714,287
75,666 Added 620.16%
87,867 $669,000
Q4 2021

Feb 08, 2022

SELL
$2.47 - $5.55 $58,561 - $131,584
-23,709 Reduced 66.02%
12,201 $33,000
Q3 2021

Nov 15, 2021

BUY
$2.63 - $4.12 $15,816 - $24,777
6,014 Added 20.12%
35,910 $94,000
Q2 2021

Sep 13, 2021

BUY
$3.94 - $5.44 $117,790 - $162,634
29,896 New
29,896 $124,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $228M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.